methods of treating a patient with an inflammatory or autoimmune disease with natalizumab and using natalizumab to treat a patient with an inflammatory or autoimmune disease

摘要

METHODS OF TREATING A PATIENT WITH AN INFLAMMATORY OR AUTOIMMUNE DISEASE WITH NATALIZUMAB AND USING NATALIZUMAB TO TREAT A PATIENT WITH AN INFLAMMATORY OR AUTOIMMUNE DISEASE Natalizumab is a safe and effective treatment for inflammatory diseases and multiple sclerosis, such as Crohn's disease, such as autoimmune disease, such as Crohn's disease. and rheumatoid arthritis. Chain switching between natalizumab and IgG4 molecules acts to reduce the level of bivalent natalizumab present after administration of natalizumab, and thus to lower natalizumab activity in the patient. Differences in JgG4 levels across patients or within a single patient over time may change natalizumab's pharmacokinetic profile. Patients with lower IgG4 levels may experience natalizumab nadir levels during a dosing period. Monitoring of IgG4 and / or natalizumab levels, and determination of a dose or dosing period based on monitoring may improve the safety and / or effectiveness of natalizumab therapy.